[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589951":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":62,"collaborators":66,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":40,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":40,"enrollmentInfo":79,"targetDuration":40,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":44,"whyStopped":40,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention: I-124 PET\u002FCT","EXPERIMENTAL","All participants will be administered an oral dose of 60 to 85 megabecquerel (MBq) +\u002F- 10% for I-124 (capsule) prior to the Positron Emission Tomography (PET) imaging. Scan coverage will extend from the vertex to the mid-thighs and in certain circumstances, coverage may be extended to the toes. Imaging will be acquired 20-28 hours after I-124 administered. Participants will be followed up for any adverse events for up to 5 days after the scan has been completed.",[13,14],"Drug: Iodine-124","Procedure: Positron Emission Tomography (PET)\u002FComputerized tomography (CT)",[16,24],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Iodine-124","Given Orally",[9],[22,23],"I-124","I-124 Radioisotope",{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"PROCEDURE","Positron Emission Tomography (PET)\u002FComputerized tomography (CT)","Combination of PET and CT imaging",[9],[30],"PET\u002FCT",[32],{"name":33,"affiliation":5,"role":34},"Thomas Hope, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Maya Aslam","CONTACT","(415) 514-8987",null,"Maya.Aslam@ucsf.edu",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","San Francisco","California","94122","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-122.41942,37.77493,{"lat":54,"lon":53},[57,58,61],{"name":37,"role":38,"phone":40,"phoneExt":40,"email":41},{"name":40,"role":38,"phone":59,"phoneExt":40,"email":60},"877-827-3222","cancertrials@ucsf.edu",{"name":33,"role":34,"phone":40,"phoneExt":40,"email":40},{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"SPONSOR_INVESTIGATOR","Thomas Hope","Principal Investigator",[67],{"name":68,"class":69},"United States Department of Defense","FED","100589951","phase-2-comparison-of-i-124-petct-for-the-diagnosis-of-thyroid-cancer-100589951",false,"NCT06961084","Comparison of I-124 PET\u002FCT for the Diagnosis of Thyroid Cancer","Comparison of I-124 PET\u002FCT to I-123 Whole Body Imaging for the Diagnosis of Thyroid","Inclusion Criteria:\n\n1. Age \\>= 13 years.\n2. Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.\n3. Meeting criteria for one of the following two populations:\n\n   1. American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.\n   2. Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.\n4. Undergone total thyroidectomy.\n5. Planned I-123 imaging within 45 days after enrollment.\n6. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.\n2. Known pregnancy.","ALL","13 Years",{"count":80,"type":81},62,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.",[87],"Thyroid Cancer",[89],"Imaging Studies","2026-06-16",{"date":92,"type":93},"2026-06-18","ACTUAL",{"date":95,"type":93},"2025-12-04",{"date":97,"type":81},"2028-04-01",{"name":64,"class":6},1]